M
Michael S. Firstenberg
Researcher at The Medical Center of Aurora
Publications - 221
Citations - 5464
Michael S. Firstenberg is an academic researcher from The Medical Center of Aurora. The author has contributed to research in topics: Extracorporeal membrane oxygenation & Ventricular assist device. The author has an hindex of 30, co-authored 213 publications receiving 4858 citations. Previous affiliations of Michael S. Firstenberg include The Ohio State University Wexner Medical Center & Northeast Ohio Medical University.
Papers
More filters
Journal ArticleDOI
Doppler-Derived Myocardial Systolic Strain Rate Is a Strong Index of Left Ventricular Contractility
Neil L. Greenberg,Michael S. Firstenberg,Peter L. Castro,Michael L. Main,Agnese Travaglini,Jill Odabashian,Jeanne K. Drinko,L. Leonardo Rodriguez,James D. Thomas,Mario J. Garcia +9 more
TL;DR: TDE-derived &egr;′p and &egR;′m are strong noninvasive indices of LV contractility, and appear to be more reliable than Sm by eliminating translational artifact.
Journal ArticleDOI
Color M-mode Doppler flow propagation velocity is a preload insensitive index of left ventricular relaxation: animal and human validation.
Mario J. Garcia,Nicholas G. Smedira,Neil Greenberg,Michael L. Main,Michael S. Firstenberg,Jill Odabashian,James D. Thomas +6 more
TL;DR: The results indicate that color M-mode Doppler v(p) is not affected by preload alterations and confirms that LV relaxation is its main physiologic determinant in both animals during varying lusitropic conditions and in humans with heart disease.
Journal ArticleDOI
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
Dominick J. Angiolillo,Michael S. Firstenberg,Matthew J. Price,Pradyumna E. Tummala,Martin Hutyra,Ian J. Welsby,Michele D. Voeltz,Harish Chandna,Chandrashekhar Ramaiah,Miroslav Brtko,Louis Cannon,Cornelius M. Dyke,Tiepu Liu,Gilles Montalescot,Steven V. Manoukian,Jayne Prats,Eric J. Topol +16 more
TL;DR: Among patients who discontinue thienopyridine therapy prior to cardiac surgery, the use of cangrelor compared with placebo resulted in a higher rate of maintenance of platelet inhibition.
Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery
Dominick J. Angiolillo,Michael S. Firstenberg,Matthew J. Price,Pradyumna E. Tummala,Martin Hutyra,Ian J. Welsby,Michele D. Voeltz,Harish Chandna,Chandrashekhar Ramaiah,Miroslav Brtko,Louis Cannon,Cornelius M. Dyke,Tiepu Liu,Gilles Montalescot,Steven V. Manoukian,Jayne Prats,Eric J. Topol +16 more
TL;DR: Cagalj et al. as discussed by the authors evaluated the use of cangrelor, an intravenous, reversible P2Y(12) platelet inhibitor for bridging thienopyridine-treated patients to coronary artery bypass grafting (CABG) surgery.
Journal ArticleDOI
The 2019-2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper
Stanislaw P Stawicki,Rebecca Jeanmonod,Andrew C. Miller,Lorenzo Paladino,David F. Gaieski,Anna Q Yaffee,Annelies De Wulf,Joydeep Grover,Thomas J Papadimos,Christina Bloem,Sagar Galwankar,Vivek Chauhan,Michael S. Firstenberg,Salvatore Di Somma,Donald Jeanmonod,Sona M Garg,Veronica Tucci,Harry L. Anderson,Lateef Fatimah,Tamara J. Worlton,Siddharth P. Dubhashi,Krystal S Glaze,Sagar Sinha,Ijeoma Nnodim Opara,Vikas Yellapu,Dhanashree S. Kelkar,Ayman El-Menyar,Vimal Krishnan,S Venkataramanaiah,Yan Leyfman,Hassan Al Thani,Prabath W. B. Nanayakkara,Sudip Nanda,Eric Cioè-Peña,Indrani Sardesai,Shruti Chandra,Aruna Munasinghe,Vibha Dutta,Silvana Teixeira Dal Ponte,Ricardo Izurieta,Juan A. Asensio,Manish Garg +41 more
TL;DR: Current state-of-science, mitigation strategies, possible therapies, ethical considerations for healthcare workers and policymakers, as well as lessons learned for this evolving global threat and the eventual return to a “new normal” are discussed.